Polymyalgia Rheumatica (PMR) and Polymyalgia Rheumatica-like (PMR-like) Manifestations in Cancer Patients Following Treatment with Nivolumab and Pembrolizumab: Methodological Blurred Points Identified Through a Systematic Review of Published Case Reports
<b>Background</b>: Among rheumatologic diseases following therapy with immune checkpoint inhibitors (ICIs), the cases of cancer patients diagnosed as having polymyalgia rheumatica (PMR), particularly with nivolumab and pembrolizumab, has been steadily rising in published reports. <b&g...
Saved in:
| Main Authors: | Ciro Manzo, Marco Isetta, Alberto Castagna, Melek Kechida |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Medical Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3271/13/2/34 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
POLYMYALGIA RHEUMATICA
by: A. M. Satybaldyev, et al.
Published: (2018-05-01) -
After what time interval are we justified to diagnose immune checkpoint inhibitor-mediated polymyalgia rheumatica?
by: Ciro Manzo, et al.
Published: (2025-03-01) -
REVIEW OF RECOMMENDATIONS FOR THE MANAGEMENT OF POLYMYALGIA RHEUMATICA (ACR/EULAR 2015)
by: M. T. Vatutin, et al.
Published: (2016-03-01) -
The evolution of diagnosis of polymyalgia rheumatica
by: A. M. Satybaldyev
Published: (2019-12-01) -
18F-FDG-PET/CT for polymyalgia rheumatica: agreement and diagnostic accuracy of routine PET scan report vs. standardized PMR PET scores
by: Kornelis S. M. van der Geest, et al.
Published: (2025-03-01)